[Intrauterine herpes simplex virus infection].
BACKGROUND
Early fetal herpes simplex virus (HSV) infection is rarely documented. Only the minority of affected fetuses survive this condition.


METHODS
At 19 weeks of gestation the first episode of a genital HSV-infection of a pregnant woman was treated with local interferon beta. At 34 weeks of gestation hydrocephalus with secondary microcephaly and microphthalmia of both eyes was detected by ultrasonography. In the amniotic fluid HSV type 2 (HSV-2) was isolated and HSV-2-DNA was detected by PCR. The serum of the mother proved positive for HSV-2 (glycoprotein G2)-specific IgG-antibodies. No other infectious causes were apparent on further testing. At 35 + 4 weeks gestation a small-for-gestational-age neonate (2130 g) with microcephaly (29 cm head circumference) was born by spontaneous vaginal delivery. Scarce ulcerative skin lesions and vesicles, hepatosplenomegaly and microphthalmia were diagnosed. Furthermore, encephalomalacia with parenchymal destruction, cataract of both eyes and aplasia of the maculae and papillae were found. HSV-2-PCR was tested positive in chorionic cells and an umbilical segment of the placenta as well as in swabs from both eyes, throat, and a herpetic skin lesion collected during the first 5 days of life. HSV-IgM-antibodies were found in the umbilical cord blood. Local and intravenous treatment with aciclovir was started. The infant exhibited signs of a severely malfunctioning central nervous system. At the age of 4 months the boy suffered from generalised cerebral seizures. He died at the age of 9 months as a consequence of respiratory insufficiency with consecutive circulation failure.


RESULTS
The case of an intrauterine HSV-2-infection is presented. The time of onset of fetal infection was most probably at the time of the maternal disease (19 weeks of gestation). Inspite of the very early infection the fetus did not die in utero.


CONCLUSIONS
Especially, if a primary genital HSV-2-infection of a pregnant woman is suspected, which can be proven by serological means only several weeks after infection, systemic therapy of the mother with aciclovir should be considered since materno-fetal transmission may occur due to the risk of maternal viraemia.
Hoppen
T
T
Zentrum für Kinderheilkunde, Abt. für Neonatologie, Universität Bonn.
Eis-Hübinger
A M
AM
Schild
R L
RL
Enders
G
G
Hansmann
M
M
Rister
M
M
Bartmann
P
P
D000015:Abnormalities, Multiple / Q000821:virology*; D000212:Acyclovir / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005315:Fetal Diseases / Q000517:prevention & control / Q000821:virology*; D006558:Herpes Genitalis / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006561:Herpes Simplex / Q000150:complications / Q000188:drug therapy / Q000821:virology*; D018258:Herpesvirus 2, Human / Q000302:isolation & purification; D006801:Humans; D007231:Infant, Newborn; D016899:Interferon-beta / Q000627:therapeutic use; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control* / Q000821:virology; D011256:Pregnancy Outcome
D000998:Antiviral Agents; D016899:Interferon-beta; D000212:Acyclovir